ACADIA: A Pivotal Catalyst Looms as the Pipeline Takes Center Stage
Commercial execution shines with DAYBUE STIX and EU approval, but all eyes turn to the imminent Phase II readout for remlifanserin in Alzheimer's disease psychosis.
ACAD · Earnings Call · 2026-08-04
Commercial Momentum: STIX and the Path to Europe
ACADIA delivered another strong quarter, with total revenues of $308 million, up 17% year-over-year on an adjusted basis. The standout story is the rapid adoption of DAYBUE STIX, the new powder formulation, which now accounts for roughly 40% of all U.S. DAYBUE patients by the end of the quarter. As Tom Garner noted, “approximately 40% of all U.S. DAYBUE patients were receiving STIX by the end of the quarter” — Thomas Garner, Chief Commercial Officer · 2026-08-04. This uptake is driving a raise in DAYBUE guidance to $480–510 million and reinforces the path toward the 2028 $700 million ambition. The other major commercial milestone is the CHMP opinion for DAYBUE (trofinetide) in Europe. After a re-examination, ACADIA received a positive opinion, setting up a European Commission decision later this quarter and a planned launch in Germany in Q4. This marks a significant expansion beyond the U.S. and adds a new growth vector. As Catherine Owen Adams emphasized, “this outcome represents a significant win for patients with Rett syndrome across Europe” — Catherine Owen Adams, Chief Executive Officer · 2026-08-04. The company is also mobilizing a highly experienced commercial team and will submit pricing and market access submissions in its planned launch markets this year, with Germany as the starting point.The Coming Catalyst: remlifanserin and the ADP Readout
While commercial execution is strong, the most important near-term event is the upcoming Phase II readout for remlifanserin in Alzheimer's disease psychosis. Enrollment is complete, and top-line results are expected in September–October. The company has also started Phase III enrollment in an operationally seamless design, allowing sites to begin screening once Phase II completed. As Elizabeth Thompson explained on the last call, “we continue to feel very good about that August to October time frame” — Elizabeth Thompson, Head of Research and Development · 2026-05-06, which has now narrowed to September–October. The stakes are high: Catherine called it "transformational," with a peak sales potential of $4 billion across ADP and Lewy body dementia psychosis. The trial design incorporates an enriched patient population and a primary endpoint of SAPS-H+D, powered for a moderate effect size of 0.4. The company is also leveraging receptor occupancy data and a more sensitive endpoint to differentiate the program. The market is clearly pricing in this binary event: the stock has climbed ~36% over the past three months, per the recent 90-day tape, and the narrative has shifted from commercial execution to pipeline potential. In the prior quarter, Elizabeth had laid out the powering assumptions, noting “we have powered for a moderate effect size, so 0.4” — Elizabeth Thompson, Head of R&D · 2026-02-26. The continued execution on both commercial brands and the newly achieved EU milestone provide a solid foundation, but the market's attention is squarely on this readout.The coming months will determine whether ACADIA transitions from a two-product commercial company to a company with a potential blockbuster in the pipeline. The evidence is strong that the narrative has shifted. With DAYBUE STIX momentum and the EU approval behind it, ACADIA is positioned to capitalize on its commercial strengths while the pipeline catalyst looms large. Total revenue reached $268M in Q1 2026 (latest fundamental data), and Q2 2026 reported at $308M, reflecting a multi-year upward trajectory.If successful, remlifanserin has the potential to be transformational for ACADIA with peak sales potential of estimated $4 billion across Alzheimer's disease psychosis and Lewy body dementia psychosis.